Angioedema
MONDO:0010481Swelling involving the deep dermis, subcutaneous, or submucosal tissues, representing localized edema. Angioedema often occurs in the face, lips, tongue, and larynx.
Also known as: Edemas, angioneurotic, Quincke edema, Quincke oedema, Quincke's edema, Quincke's oedema, Quinckes edema, Quinckes oedema, Urticarias, giant
67 clinical trials for this condition and its sub-types, 19 tagged with Angioedema itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Angioedema
-
Hereditary angioedema 58 trials · 60 incl. sub-types
10 sub-types
- Hereditary angioedema with C1Inh deficiency 14 trials · 32 incl. sub-types Sub-types →
- Hereditary angioedema type 3 2 trials
- Hereditary angioedema with normal C1Inh 2 trials
- PLG-related hereditary angioedema with normal C1inh 0 trials
- Angioedema, hereditary, 4 0 trials
- Angioedema, hereditary, 5 0 trials
- Angioedema, hereditary, 6 0 trials
- Angioedema, hereditary, 7 0 trials
- Angioedema, hereditary, 8 0 trials
- Hereditary angioedema with normal C1inh not related to F12 or PLG variant 0 trials
-
Acquired angioedema 2 trials · 3 incl. sub-types
5 sub-types
- Renin-angiotensin-aldosterone system-blocker-induced angioedema 2 trials
- Acquired angioedema with C1Inh deficiency 1 trial
- Acquired angioedema type 1 0 trials
- Acquired angioedema type 2 0 trials
- Vibratory angioedema 0 trials
-
Non-histaminic angioedema 2 trials
Most studied deeper sub-types
-
New hope for HAE: Long-Term trial of navenibart launches
Disease control By invitation onlyThis Phase 3 trial tests the long-term safety and effectiveness of navenibart, an injectable drug, in 145 adults and teens with hereditary angioedema (HAE) who were in a previous study. The trial has two parts: first, everyone gets a fixed dose; then, some may switch to a persona…
Phase 3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New shot could stop dangerous swelling attacks in HAE
Disease control OngoingThis Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…
Phase 3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New daily pill could stop painful swelling attacks for HAE patients
Disease control OngoingThis Phase 3 trial tests whether a once-daily pill called deucrictibant can prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks, and researchers count how many attacks occur. …
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Smartphone app study to track rare swelling attacks cancelled
Knowledge-focused CancelledThis study aimed to learn more about the unpredictable swelling attacks in people with bradykinin-mediated angioedema, a rare condition that can cause life-threatening airway swelling. Participants would have used a smartphone app daily to report attacks and possible triggers. Th…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC